Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Blindness 100%
• Dexamethasone 100%
• Remdesivir 100%
• Baricitinib 100%
• Adverse Event 31%
• Survival 15%
• Oxygen 10%
• Infection 10%
• Drug 5%
• Death 5%
• Side Effect 5%
• Allergy 5%
• Comorbidity 5%
• Immunomodulation 5%
• SARS Coronavirus 5%

INIS

• patients 100%
• adults 100%
• dexamethasone 100%
• covid-19 100%
• ventilation 31%
• risks 21%
• oxygen 10%
• populations 10%
• males 10%
• administration 5%
• drugs 5%
• laboratories 5%
• design 5%
• comparative evaluations 5%
• death 5%
• doses 5%
• cost 5%
• allergy 5%
• side effects 5%
• infectious diseases 5%
• usa 5%
• females 5%
• japan 5%
• mexico 5%
• alaska 5%
• south korea 5%
• american indians 5%
• singapore 5%
• safety analysis 5%

Keyphrases

• Administration Costs 5%
• Block Design 5%